プレスリリース

Illumina to Announce Third Quarter 2011 Financial Results on Tuesday, October 25, 2011

Updated Time

SAN DIEGO, Oct 18, 2011 (BUSINESS WIRE) --

Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for third quarter 2011 before market open on Tuesday, October 25, 2011.

On the same day, at 5:00am Pacific Time (8:00am Eastern Time) Jay Flatley, President and Chief Executive Officer, and Christian Henry, Senior Vice President, Chief Financial Officer, and General Manager, Life Sciences, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.

Conference Call Details

The conference call will begin at 5:00am Pacific Time (8:00am Eastern Time) on Tuesday, October 25, 2011. Interested parties may listen to the call by dialing 800.573.4842 (passcode: 87293748), or if outside North America, by dialing +1.617.224.4327 (passcode: 87293748). Individuals may access the live teleconference in the Investor Relations section of Illumina's web site under the "Company" tab at www.illumina.com.

A replay of the conference call will be available from 8:00am Pacific Time (11:00pm Eastern Time) on October 25, 2011 through November 1, 2011 by dialing 888.286.8010 (passcode: 74207499), or if outside North America, by dialing +1.617.801.6888 (passcode: 74207499).

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.

SOURCE: Illumina, Inc.

Illumina, Inc.
Investors:
Kevin Williams, MD, Investor Relations
858-332-4989
kwilliams@illumina.com
or
Media:
Laura Trotter, Public Relations
858-882-6822
pr@illumina.com

Recent Articles

英国がゲノム研究とより良いヘルスケアの新しい基準をどのように設定しているか
英国がゲノム研究とより良いヘルスケアの新しい基準をどのように設定しているか
Shriners Children’s big bet on the future of specialized pediatric care
Shriners Children’s big bet on the future of specialized pediatric care
Illumina highlights the importance of HRD testing at ESMO 2023
Video: Illumina highlights the importance of HRD testing at ESMO 2023